Publications (PubMed ID)

Sharma SK, Dey AB, Agarwal N, Nagarkar KM, Gujral S. Tuberculosis: A rare cause of splenic abscess. Journal of Association of Physician India. 1999: 47(7): 740-1. PMID: 10778602.
Agarwal N, Handa R, Acharya SK, Wali JP, Dinda AK, Aggarwal P. A study of autoimmune markers in Hepatitis C infection. Indian Journal of Medical Research. 2001: 113:170-174. PMID: 11968950
Agarwal N, Cherascu B. Concomitant acral necrosis and hemolytic uremic syndrome following ingestion of quinine. Journal of Postgraduate Medicine. 2002: 48(3):197-198. PMID:12432194
Agarwal N, Klix M, Burns CP. Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance. Annals of Internal Medicine. 2004: 141(1): 83-4. PMID: 15238389
Agarwal N, Spahr JE, Werner TL, Newton DL, Rodgers GM. Acquired amegakaryocytic thrombocytopenic purpura. American Journal of Hematology. 2006: 81(2):132-5. PMID: 16432869
Agarwal N, Tepe E, Mishra A, Ward JH. Relapse of acute promyelocytic leukemia presenting as granulocytic sarcoma in the hip. Annals of Hematology. 2006: 85(10):741-2. PMID:16718497
Nordin TA, Hartz AJ, Noyes Jr R, Anderson MC, Rosenbaum ME, James PA, Ely JW, Agarwal N, Levy BT. Empirically identified goals for the management of unexplained symptoms. Family Medicine. 2006: 38(7): 476-82. PMID:16823672
Agarwal N, Werner TL, Carney HM, Rodgers GM. Management of cancer associated thrombotic microangiopathy: What is the right approach? American Journal of Hematology. 2007: 82(4): 295-8. PMID:17034030
Agarwal N, Spahr JE, Rodgers GM. Successful management of intra-abdominal hemorrhage in presence of severe alcoholic liver disease with activated recombinant factor VII (NovoSeven)”. A case report and review of the literature on approved and off label use of recombinant activated factor VII (rFVIIa). Blood Coagul Fibrinolysis. 2007: 18(2): 205-7. PMID:17287641
Agarwal N, Gordeuk VR, Prchal JT. Are erythropoietin receptors expressed in tumors? Facts and Fiction; More Careful Studies Needed. Journal of Clinical Oncology. 2007: 25(13): 1813-4: author reply 1815. PMID:17470878
Agarwal AM, Agarwal N, Glenn MJ, Lim MS. Blastic Transformation of Low Grade Follicular Lymphoma. Journal of Clinical Oncology. 2007: 25(16): 2326-8. PMID:17538181
Agarwal N, Fletcher D, Ward JH. Obesity and Treatment of Prostate Cancer: What is the Right Dose of Lupron Depot? Clinical Cancer Research. 2007: 13(13):4027. PMID:17606739
Agarwal N, Kutlar F, Mojica-Henshaw MP, Ou CN, Gaikwad A, Reading S, Bailey L, Kutlar A, Prchal JT. Missense Mutation of the Last Nucleotide of Exon 1 (G->C) of β globin Gene not only leads to Undetectable Mutant Peptide and Transcript but also interferes with the Expression of Wild Allele. Haematologica. 2007: 92(12):1715-6. PMID:18056002
Agarwal N, Mojica-Henshaw MP, Simmons ED, Hussey D, Ou CN, Prchal JT. Familial Polycythemia Caused by a Novel Mutation in the Beta Globin Gene: Essential Role of P50 in Evaluation of Familial Polycythemia. International Journal of Medical Sciences. 2007: 4(4):232-PMID: 17952198
Anderson M, Hartz A, Nordin T, Rosenbaum M, Noyes R, James P, Ely J, Agarwal N, Anderson S. Strategies Used by Community Clinicians to Manage Patients with Medically Unexplained Symptoms. Family Medicine. 2008: 40(2): 111-8. PMID:18247177
Agarwal N, Gordeuk VR, Prchal JT. Genetic Mechanisms Underlying Regulation of Hemoglobin Mass. Advances in Experimental Medicine and Biology. 2007: 618:195-210. PMID:18269198
Yoon D, Agarwal N, Prchal JT. Does Erythropoietin Promote Tumor Growth? Clinical Cancer Research 2008: 14(6):1920; author reply 1920-1. PMID:18347197
Wada D, Agarwal N, Florell S, Lim, MS. Recurrent squamous cell carcinoma and follicular lymphoma arising in the scalp after treatment for lymphoma. Pathology 2008:40(3):316-20. PMID:18428060
Agarwal N*, Swierczek S*, Nussenzveig R, Rothstein G, Wilson A, Artz A, Prchal J. Hematopoiesis is Not Clonal in Healthy Elderly Females? Blood. 2008: 112(8):3186-93 (*first co- author). PMID: 18641369.
Agarwal N, Prchal JT. Erythropoietic Agents and the Elderly. Seminars in Hematology 2008: 45(4): 267-275. PMID:18809098
Chen A, Agarwal N. Reversible Posterior Leukoencephalopathy Syndrome Associated with Sunitinib. Internal Medicine Journal. 2009: 39(5): 341-2. PMID:19382984
Lim HY, Agarwal AM, Agarwal N, Ward JH. Recurrent Epistaxis as a Presenting Sign of Androgen-Sensitive Metastatic Prostate Cancer. Singapore Medical Journal 2009: 50(5):e178-80. PMID:19495504
Agarwal N, Hussain M. Management of Bladder Cancer: Current and Emerging Strategies. Drugs. 2009: 69(9):1173-87. PMID: 19537835
Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Journal of National Comprehensive Cancer Network (JNCCN). 2009: 7(6):618-30. PMID:19555584
Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Journal of National Comprehensive Cancer Network (JNCCN). 2009: 7(6): 672-93: PMID:19555582
Agarwal N, Nussenzveig RH, Swierczek SI, Parker CJ, Prchal JT. Does HUMARA assay for assessment of clonal hematopoiesis have shortcomings? Blood. 2009; 114(11): 2357-8. PMID:19745079
Agarwal N, Batten J. Optimal Treatment Options in the Post Orchiectomy Management of Clinical Stage 1 Seminoma. Oncology (Williston Park). 2009: 23(9):764,767. PMID:19777761
Agarwal N, Prchal JT. Anemia of Chronic Disease (Anemia of Inflammation). Acta Haematologica. 2009:122(2-3):103-8. PMID:19907147
Agarwal, N. Hormonal therapy use for prostate cancer and cardiovascular mortality in men. Journal of American Medical Association (JAMA). 2010: 303(1):32-3; author reply 33. PMID: 20051564
Narayanan S, Duffin KC, Batten J, Agarwal N. Improvement of Psoriasis during Sunitinib Therapy for Renal Cell Carcinoma. American Journal of Medical Sciences. 2010: 339(6):580- 1. PMID:2042178
Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G. Abiraterone acetate: a promising drug for the treatment of castration resistant prostate cancer. Future Oncology. 2010: 6(5):665-79. PMID:20465382
Montejo M, Bentz B, Hunt J, Buchman L, Agarwal N, Hitchcock Y. IMRT with Simultaneous Integrated Boost and Concurrent Chemotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology, Biology, Physics. 2011: 81(5): 845-52. PMID:21167654
Agarwal N, Sonpavde G, Sartor O. Cabazitaxel in the treatment of castration refractory prostate cancer. Future Oncology. 2011: 7(1):15-24. PMID:21174534
Agarwal N, Vogelzang NJ. Secondary hormonal manipulations in the treatment of castration refractory prostate cancer. BJU International. 2011: 108(2):227-8. PMID:21410863
Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW. Immunotherapy for the treatment of prostate cancer. Expert Opinion in Biological Therapy. 2011: 11(8): 997-1009.PMID:21675925
Agarwal N. Editorial comment on “a Phase II Clinical Trial of Neoadjuvant Ketoconazole and Docetaxel Chemotherapy Prior to Radical Prostatectomy in High-Risk Patients”. Journal of Urology. 2011: 186(3): 887; author reply 888. PMID:21791349
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney Cancer. Journal of National Comprehensive Cancer Network. 2011: 9(9):960-77. PMID:21917622
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy of advanced renal cell carcinoma. Journal of Clinical Oncology 2012: 30(12):1371-7. PMID: 22430274
Agarwal N, Sonpavde G, Sternberg CN. Novel Molecular Targets for the Therapy of Castration- Resistant Prostate Cancer. European Urology. 2012: 61(5):950-60.PMID:22209376
Swierczek SI, Piterkova L, Jelinek J, Agarwal N, Hammoud S, Wilson A, Hickman K, Parker CJ, Cairns B, Prchal JT. Methylation of AR Locus Does Not Always Reflect X Chromosome Inactivation State. Blood 2012: 19(13):e100-9. PMID: 22286197.
Agarwal N, Padmanbh S, Vogelzang NJ. Development of novel immune interventions for prostate cancer. Clinical Genitourinary Cancer 2012: 10(2):84-92. PMID:22409862
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular Cancer. Journal of National Comprehensive Cancer Network (JNCCN). 2012: 10(4):502-35. PMID:22491049
Harshman LC, Xie W, Bjarnason G, Knox J, MacKenzie M, Wood L, Srinivas S, Vaishampayan U, Tan MH, Rha SY, Donskov FN, Agarwal N, Kollmannsberger C, North S, Rini BI, Heng DY, Choueiri TK. Conditional survival of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor (VEGF) targeted therapy: results from the International Metastatic RCC Database Consortium. Lancet Oncology. 2012: 13(9):927-35. PMID: 22877847.
Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan K, Jafri N, Korte S, Lipson B, Yunis F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC). Journal of National Comprehensive Cancer Network (JNCCN). 2012: 10(11):1391-8. PMID: 23138167.
Al-Marrawi MY, Rini BI, Harshman LC, Bjarnason G, Wood L, Vaishampayan U, Mackenzie M, Knox JJ, Agarwal N, Al-Harbi H, Kollmannsberger C, Tan MH, Rha SY, Donskov FN, North S, Choueiri TK, Heng DY; For the International mRCC Database Consortium. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF- targeted therapy in metastatic renal cell carcinoma patients.Targeted Oncology. 2013: 8(3): 203-9. PMID: 23300029
Heng DY, Xie W, Regan MM, Harshman LC, Bjarnason G, Vaishampayan U, MacKenzie MJ, Wood LA, Donskov F, Tan MH, Rha SY, Agarwal N, Kollmannsberger CK, Rini BI, and Choueiri TK. External validation of the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model and comparison to other models in the era of targeted therapy. Lancet Oncology. 2013:14(2):141-8. PMID: 23312463.
Agarwal N,# Maughan B#, Hussain SA, Boucher KM, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G. (# Equal contribution, first co-authors). Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clinical Genitourinary Cancer. 2013: 11(3):316-20. PMID: 23332638.
Clark PE , Agarwal N , Biagioli MC , Eisenberger MA , Greenberg RE , Herr HW , Inman BA , Kuban DA , Kuzel TM , Lele SM , Michalski J , Pagliaro LC , Pal SK , Patterson A , Plimack ER , Pohar KS , Porter MP , Richie JP , Sexton WJ , Shipley WU , Small EJ , Spiess PE , Trump DL , Wile G , Wilson TG , Dwyer M , Ho M. (2013). Bladder Cancer. Journal of the National Comprehensive Cancer Network, 2013: 11(4):446-75. PMID: 23584347.
Agarwal N‡, Zhang TY‡, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ. (‡Equal contribution, first co-authors). Management of castrate resistant prostate cancer – recent advance and optimal sequence of treatments. Current Urology Report. 2013: 14(3):174-83. PMID: 23559076.
Campo RA, O’Connor K, Light KC, Nakamura Y, Lipschitz D, LaStayo PC, Pappas L, Boucher K, Irwin MR, Agarwal N, & Kinney AY. Feasibility and Acceptability of a Tai Chi Chih Randomized Controlled Trial in Senior Female Cancer Survivors. Integrative Cancer Therapies. 2013:12(6): 464-74. PMID: 23620504.
Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile Cancer. Journal of the National Comprehensive Cancer Network (JNCCN). 2013:11(5): 594-615. PMID: 23667209.
Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, and Heng DYC. Metastatic non clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium (IMDC) Criteria. Cancer. 2013: 119(16):2999-3006. PMID: 23696129.
Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Lorenzo GD, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G. Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design. Clinical Genitourinary Cancer. 2013: 11(4):495-500. PMID: 23800847.
Patel JC, Maughan BL, Agarwal AM, Batten JM, Zhang TY, Agarwal N. Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer. Prostate Cancer. 2013: 981684. PMID: 23819055.
Birmingham WC, Agarwal N, Kohlmann W, Aspinwall LG, Wang M, Bishoff J, Dechet C, Kinney AY. Patient and provider attitudes toward genomic testing for prostate cancer susceptibility: a mixed method study. BMC Health Services Research. 2013: 13:279. PMID:23870420
Quinn DI, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Carducci M, Monk PJ, Twardowski PW, Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang N, Thompson IM. A Randomised Trial of Docetaxel and Atrasentan compared to Docetaxel and Placebo for Men with Advanced Castration Resistant Prostate Cancer: SWOG S0421. Lancet Oncology. 2013: 14(9):893-900.PMID: 23871417.
Nelson Q, Agarwal N, Stephenson R, Cannon Albright L. A population-based analysis of clustering identifies a strong genetic contribution to lethal prostate cancer. Frontiers in Genetics. 2013: 4:152 PMID: 23970893.
Light KC, Agarwal N, Iacob E, White AT, Kinney AY, Van Haitsma T, Aizad H, Hughen RW, Bateman L, Light AR. Altered Leukocyte Gene Expression Profiles Associated with Fatigue in Patients with Prostate Cancer versus Chronic Fatigue Syndrome. Psychoneuroendocrinology. 2013: 38(12):2983-95. PMID: 24054763.
Swierczek S, Agarwal A, Naidoo K, Lorenzo FR, Whisenant J, Agarwal N, Coetzer TL, Prchal JT. Novel Exon 2 alpha Spectrin Mutation and Intragenic Crossover: Three Morphological Phenotypes Associated with Four Distinct alpha Spectrin Defects. Haematologica. 2013: 98(12):1972-9. PMID: 24077844
Agarwal N, Hussain M. Management of newly diagnosed metastatic prostate cancer. Hematology/Oncology Clinics of North America. 2013: 27(6): 1221-41. PMID: 24188260.
Sangle N, Mao R, Shetty S, Schiffman J, Dechet C, Layfield L, Agarwal N, Liu T. Novel molecular aberrations and pathologic findings in tubulocystic variant of renal cell carcinoma. Indian Journal of Pathology & Microbiology. 2013: 56(4): 428-33. PMID: 24441240.
Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamis A, Kollmannsberger CK, North SA, Rini BI, Heng DY. Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma (RCC) in the Era of Targeted Therapy. European Urology. 2014: 65(6) 1086-92. PMID: 23916693.
Alwan LM, Grossmann K, Sageser D, Van Atta J, Agarwal N, Gilreath JA. Comparison of Acute Toxicity and Mortality after Two Different Dosing Regimens of High-Dose Interleukin-2 for Patients with Metastatic Melanoma. Targeted Oncology. 2014:9(1):63-71. PMID: 23609056.
Bendell JC, Gordon MS, Hurwitz HI, Jones S, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S. Safety, Pharmacokinetics, Pharmacodynamics and Antitumor Activity of Dalantercept (ACE-041), a Soluble Activin Receptor- Like Kinase-1 Ligand Trap, in Patients with Advanced Solid Tumors. Clinical Cancer Research. 2014: 20(2):480-9. PMID: 24173543.
Campo RA, Agarwal N, LaStayo P, O’Connor K, Gardner J, Smith S, Pappas L, Boucher K, Light KC, & Kinney AY. Effects of a 12-week randomized Qigong intervention on senior prostate cancer survivors’ levels of fatigue and distress. Journal of Cancer Survivorship. 2014: 8(1):60-9. PMID: 24170679.
Schutz F, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger CK, North SA, Wood LA, Vaishampayan U, Tan MF, MacKenzie MJ, Lee JL, Rha SY, Yuasa T, Heng DY, and Choueiri TK. The impact of low serum sodium on treatment outcome to targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. European Urology. 2014: 65(4):723-30. PMID: 24184025.
Gartrell B, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD*, Agarwal N*. Pulmonary complications with the use of mTOR inhibitors for cancer therapy. *Co- senior authors. Targeted Oncology. 2014: 9(3):195-204. PMID: 23852656.
Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treatment Reviews. 2014: 40(1):190-6. PMID: 23684373.
Agarwal N, Bellmunt J, Maughan B, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko Y, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-month progression- free survival as an endpoint to evaluate second-line therapy for advanced urothelial carcinoma. Clinical Genitourinary Cancer. 2014: 12(2): 130-7. PMID: 24220220
Agarwal N *,Pond GR*, Bellmunt J, Choueiri TK, Qu AQ, Fougeray R, Niegisch G, Galsky MD, Wong YN, Stadler WM, Sridhar SS, Vogelzang NJ, Sternberg CN, Sonpavde G. The impact of baseline prognostic factors on primary endpoints employed in phase II trials of second-line therapy for advanced urothelial carcinoma. BJU International. 2014: 113(5b):E137-43. *Equal contribution/ first co-authors. PMID: 24219029.
Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of Oncology. 2014: 25(1): 149-54. PMID: 24356626.
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam EL, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson DM, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Sircar K, Somer B, Wang J, Wilder RB, Dwyer M, Kumar R. Kidney Cancer, Version 2.2014. Featured Updates to the NCCN Guidelines: Non Clear Cell Variant Kidney Cancer. Journal of the National Comprehensive Cancer Network (JNCCN). 2014: 12(2):175-82. PMID: 24586079.
Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Carducci M, Monk III PJ, Datar RH, Garzotto MG, Mack PC, Lara Jr. P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a Phase 3 trial of docetaxel with or without atrasentan for metastatic castration resistant prostate cancer. Journal of Clinical Oncology. 2014: 32(11): 1136-42. PMID: 24616308.
Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J. New Agents for Prostate Cancer. Annals of Oncology. 2014: 25(9): 1700-9. PMID: 24658665.
Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY. First-, second-, third-line therapy for mRCC: benchmarks for the trial design from the IMDC. British Journal of Cancer. 2014: 110(8):1917-22. PMID: 24691425.
Hussain M, Grivas P, Agarwal N, Levine E, Mcvicar G, Puzanov I, Siefker-Radtke A, Srinivas S, Twardowski P, Eisenberger M, Quinn D, Yu E, Vaishampayan U. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). Cancer. 2014: 120(17): 2684-93. PMID: 24802654.
Cannon-Albright LA, Farnham J, Bailey M, Albright FS, Teerlink CC, Agarwal N, StephensonR, Thomas A. Identification of specific Y chromosomes associated with increased risk for prostate cancer. The Prostate. 2014: 74(9):991-8. PMID: 24796687
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry BM, Gagnier P, Liu D, Gerritsen WR. Ipilimumab versus placebo for patients with post-docetaxel metastatic castration-resistant prostate cancer (CA184-043): a multicenter, randomized, double-blind phase 3 trial. Lancet Oncology. 2014: 15(7):700-12. PMID: 24831977.
Dahal A, Bellows BK, Sonpavde G, Tantravahi SK, Choueiri TK, Galsky MD, Agarwal N. Incidence of severe nephrotoxicity with cisplatin, based on renal function eligibility criteria: Indirect comparison meta-analysis. American Journal of Clinical Oncology. 2014: May 12, Epub. PMID: 24824144.
Heng D, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaisampayan UN, Rha SY, Kim JJ, Choueiri TK. Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). European Urology. 2014: 66(4):704-10. PMID: 24931622.
Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD. Phase Ib/II Trial of Gemcitabine, Cisplatin, plus Lenalidomide as First Line Therapy in Patients with Metastatic Urothelial Carcinoma. The Oncologist. 2014: 19(9):915-6. PMID: 25052451.
Lam ET, Wong MKK, Agarwal N, Redman BG, Logan T, Flaig TW, Monk III JP, Jarkowski A, Sendilnathan A, Bolden M, Kuzel T, Olencki T. Safety and efficacy of sequencing high-dose interleukin 2 (IL2) after tyrosine kinase inhibitor (TKI) therapy for metastatic renal cell carcinoma. Journal of Immunotherapy. 2014: 37(7):360-5. PMID: 25075565.
Agarwal N, Dorff T, Goldkorn. New Prostate Cancer Drugs: Extending and Improving Life. Lancet Oncology. 2014: 15(10):1052-4. PMID: 25104108.
Campo RA, Light KC, O’Connor K, Nakamura Y, Lipschitz D, LaStayo PC, Pappas L, Boucher K, Irwin MR, Hill HR, Martins TB, Agarwal N & Kinney AY. Blood Pressure, Cortisol, and Inflammatory Cytokines in Senior Female Cancer Survivors Enrolled in a Tai Chi Chih Trial. Journal of Cancer Survivorship. 2014: Aug 28. Epub. PMID: 25164513.
Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial. International Journal of Cancer. 2014: 136(8):1856-62. PMID: 25219358.
Necchi A, Pond G, Giannatempo P, Di Lorenzo G, Eigl B, Locke J, Pal SK, Agarwal N, Poole A, Vaishampayan UN, Niegisch G, Hussain SA, Singh P, Bellmunt J, Sonpavde G. Cisplatin-based first-line therapy for advanced urothelial carcinoma following previous perioperative cisplatin-based therapy. Clinical Genitourinary Cancer. 2014: Sep 23. Epub. PMID: 25450035.
Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI. Outcome of Patients with Metastatic Sarcomatoid Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer. 2014: Sep 23. Epub. PMID: 25450036.
Fay AP, Wanling LX, Lee JL, Harshman LC, Bjarnason GA, Knox JJ, Ernst S, Wood L, Vaishamayan UN, Yuasa T, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng D. Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated with Targeted Therapies: Results From the International mRCC Database Consortium. Clinical Genitourinary Cancer. 2014: Oct 2. Epub. PMID: 25458371.
Pal SK, He M, Wilson T, Liu X, Zhang K, Carmichael C, Torres A, Hernandez S, Lau C, Agarwal N, Kawachi M, Yen Y, Jones JO. Detection and Phenotyping of Circulating Tumor Cells in High-Risk Localized Prostate Cancer. Clinical Genitourinary Cancer. 2014: Sep 22. Epub. PMID: 25450039.
Bailey EB, Tantravahi SK, Poole A, Agarwal AM, Straubhar AM, Batten JA, Patel SB, Wells CE, Stenehjem D, Agarwal N. Correlation of severity of hypothyroidism and survival outcomes in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors. Clinical Genitourinary Cancer. 2014: Nov 15. Epub. PMID: 25497584.
Reese Z, Straubhar A, Pal SK, Agarwal N. Ipilimumab in prostate cancer. Future Oncology. 2015: 11(1):27-37. PMID: 25572782.
Albright F, Stephenson RA, Agarwal N, Teerlink CC, Lowrance WT, Farnham JM, Cannon-Albright LA. Prostate cancer risk prediction based on complete prostate cancer family history. The Prostate. 2015: 75(4):390-8. PMID: 25408531.
Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono Johann, Melo Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak D, Lee SY, Webb I, Tejura B, Borgstein N, Dreicer R. A phase 3, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during the following docetaxel-based therapy: ELM-PC 5. Journal of Clinical Oncology. 2015: Jan 26. Epub. PMID: 25624429.
Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators (Agarwal, N). Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol. 2015: March 16. Epub PMID: 25701170.
Yu E, Cheng H, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan U, Agarwal N, Heath E, Pal SK, Rehman H, Leiter A, Batten J, Montgomery B, Galsky M, Antonarakis E, Chi K. Activity of enzalutamide in men with metastatic castration resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer and Prostatic Disease. 2015: Jan 20. Epub. PMID: 25600186.
Singh P, Agarwal N, Pal SK. Sequencing Systemic Therapies for Metastatic Kidney Cancer. Current Treatment Options in Oncology. 2015: Feb 4. Epub. PMID: 25648540.
Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T, Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line therapy: a population-based study. Lancet Oncology. 2015: Feb 11. Epub. PMID: 25681967.
Tantravahi SK, Albertson D, Agarwal AM, Ravulapati S, Poole A, Patel SB, Hawatmeh JS, Straubhar AM, Liu T, Stenehjem DD, Agarwal N. Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Journal of Oncology. 2015: Jan 20. Epub. PMID: 25688268.
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Kidney cancer, version 3.2015. Journal of the National Comprehensive Cancer Network (JNCCN). 2015: 13(2):151-9. PMID: 25691606
Gupta S, Gill D, Pal SK, Agarwal N. Activin receptor inhibitors-dalantercept. Current Oncology Reports. 2015: 17(4):441. PMID: 25708802.
Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology. 2015: Apr 6. Epub. PMID: 25847934.
Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Investigational New Drugs. 2015: April 21. Epub. PMID: 25895965.
Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong YN, Yu EY, Powles T, Moshier EL, Ladoire S, Hussain SA, Agarwal N, Vaishampayan UN, Recine F, Berthold D, Necchi A, Theodore C, Milowsky MI, Bellmunt J, Rosenberg JE; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer. 2015: April 14. Epub PMID: 25872978
Pal SK, Agarwal N, Jones JO. Circulating tumor cells in prostate cancer: Does (nuclear) size matter? Cancer. 2015: May 14. Epub PMID: 25980931.
Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Gupta S, Hancock SL, Kim JJ, Kuzel TM, Lam ET, Lau C, Levine EG, Lin DW, Michaelson MD, Olencki T, Pili R, Plimack ER, Rampersaud EN, Redman BG, Ryan CJ, Sheinfeld J, Shuch B, Sircar K, Somer B, Wilder RB, Dwyer M, Kumar R. Testicular Cancer, Version 2.2015. Journal of National Comprehensive Cancer Network. 2015: Jun;13(6):772-99. PMID: 26085393.
Singh P, Pal SK, Alex A, Agarwal N. Development of PROSTVAC immunotherapy in prostate cancer. Future Oncology. 2015: 11(15):2137-48. doi: 10.2217/fon.15.120. PMID: 26235179.
Horn KP, Yap JT, Agarwal N, Morton KA, Kadrmas DJ, Beardmore B, Butterfield RI, Boucher K, Hoffman JM. FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. Cancer Imaging. 2015: Sep 3;15:15. doi: 10.1186/s40644-015-0049-x. PMID: 26335224.
Werner TL, Wade ML, Agarwal N, Boucher K, Patel J, Luebke A, Sharma S. A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Investigational New Drugs. 2015: Sep 14. Epub PMID: 26365907.
Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin RA, Agarwal N, Jones JO. Clinical and translational assessment of VEGFR1 as a mediator of the pre-metastatic niche in high-risk localized prostate cancer. Molecular Cancer Therapeutics. 2015: Oct 8. pii: molcanther.0367.2015. Epub PMID: 264650920.
Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma S. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemotherapy and Pharmacology. 2015: Dec 30. Epub PMID: 26719074.
Munster PN, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner T, Dees EC, Bergsland EK, Agarwal N, Kleha JF, Durante M, Adams LM, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-kinase inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 2015: Nov 24. Epub PMID: 26603258.
Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated with Perioperative Cisplatin. Clinical Genitourinary Cancer. 2015: Oct 24. Epub PMID: 26589729.
Patel SB, Stenehjem DD, Gill DM, Tantravahi SK, Agarwal AM, Hsu J, Vuong W, Pal SK, Agarwal N. Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clinical Genitourinary Cancer. 2015: Dec 17. PMID: 26781820.
Pal SK, Agarwal N, Grivas P, Choueiri T. Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence. Journal of Clinical Oncology. 2016: Jan 19. Epub PMID: 26786913.
Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung, Higano CS. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. Journal of Clinical Oncology. 2016: Jan 25. pii: JCO649285. PMID: 26811535.
Kwiatkowski DJ, Choueiri TK, Fay AP, Rini BI, Thorner AR, De Velasco G, Tyburczy M, Hamieh L, Albiges L, Agarwal N, Ho TH, Song J, Pignon JC, Barrios PM, Michaelson MD, Van Allen EM, Krajewski KM, Porta C, Pal SK, Bellmunt J, McDermott DF, Heng DY, Gray KP, Signoretti S. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell Carcinoma. Clinical Cancer Research. 2016: Feb 1. pii: clincanres.2631.2015. PMID: 26831717.
Merriman J, Tward J, Albertson D, Dechet C, Agarwal N. Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma. Journal of Immunotherapy. 2016: Feb-Mar; 39(2):101-3. PMID: 26849079.
Agarwal N, Sonpavde G, Choueiri TK, Pal SK. Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. European Urology. 2016: Feb 9. Pii: S0302-2838(16)00164-0. PMID: 26873842.
Agarwal N, Machiels JP, Suarez C, Lewis N, Higgins M, Wisinski K, Awada A, Maur M, Stein M, Hwang A, Mosher R, Wasserman E, Wu G, Zhang H, Zieba R, Elmeliegy M. Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer. The Oncologist. 2016: Apr 18. Pii: theoncologist.2015-0502. PMID: 27091421.
Alex AB, Pal SK, Agarwal N. CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology. 2016: Apr 20. PMID: 27482286.
Agarwal N, Alex AB, Farnham JM, Patel S, Gill D, Buckley TH, Stephenson RA, Cannon-Albright L. Inherited variants in SULT1E1 and response to abiraterone acetate in men with metastatic castration refractory prostate cancer (mCRPC). Journal of Urology. 2016: May 2. pii: S0022-5347(16)30328-7. doi: 10.1016/j.juro.2016.04.079. PMID: 27150425.
Agarwal N, Shuch B, Pal SK. Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naïve Patients With Metastatic Renal Cell Carcinoma. JAMA Oncology. 2016: June 2. doi: 10.1001/jamaoncol.2016.1198. PMID: 27254305.
Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N*, Alva A* (co-corresponding author). Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunology Immunotherapy. 2016: June 8. PMID: 27277816.
Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DY, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ, METEOR Investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomized, open-label, phase 3 trial. Lancet Oncology. 2016: June 3. Pii: S1470-2045(16)30107-3. PMID: 27279544.
Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bögemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 2016: June 13. Pii: JCO669697. PMID: 27298414.
Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, Bjarnason GA, Yamamoto H, Beuselinck B, Rini BI, Knox JJ, Agarwal N, Ernst DS, Pal SK, Wood LA, Bamias A, Alva AS, Kanesvaran R, Choueiri TK, Heng DY. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology. 2016: June 15. Pii: S0302-2838(16)30258-5. Doi: 10.1016/j.eururo.2016.05.049. PMID: 27318422.
Parker SJ, Pond GR, Agarwal N, Alex A, Heilbrun ME, Sonpavde G. Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 2016: May 27. pii: S1558-7673(16)30135-5. doi: 10.1016/j.clgc.2016.05.009. PMID: 27338517.
Pal SK, Agarwal N. Kidney cancer: Finding a niche for girentuximab in metastatic renal cell carcinoma. Nature Reviews Urology. 2016: June 28. doi: 10.1038/nrurol.2016.115. PMID: 27349371.
Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clarke PE, Plimack ER. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. Journal of Clinical Oncology. 2016: July 25. Pii: JCO681429. PMID: 27458279.
Gill D, Hahn AW, Sonpavde G, Agarwal N. Immunotherapy of advanced renal cell carcinoma: Current and future therapies. Human Vaccines Immunotherapeutics. 2016: Aug 5. PMID: 27494417.
Albright FS, Stephenson RA, Agarwal N, Cannon-Albright LA. Relative Risks for Lethal Prostate Cancer Based on Complete Family History of Prostate Cancer Death. Prostate. 2016: Aug 16. doi: 10.1002/pros.23247. PMID: 27527734.
Pal SK, Karam JA, Bergerot P, Agarwal N. Developing a Clear Path Forward for Non-Clear-Cell Renal Carcinoma. Journal of Clinical Oncology. 2016: Sep 6. Pii: JCO693572. PMID: 27601540.
Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK. Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. Journal of Clinical Oncology. 2016: Sep 6. Pii: JCO667311. PMID: 27601543.
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorijian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of National Comprehensive Cancer Network. 2016: Oct 14. PMID: 27697976.
Alva A, Daniels GA, Wong MK, Kaufman HL, Morse Ma, McDermott DF, Clark JI, Agarwala SS, Miletello G, Logan TF, Hauke RJ, Curti B, Kirkwood JM, Gonzalez R, Amin A, Fishman M, Agarwal N, Lowder JN, Hua H, Aung S, Dutcher JP. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy. 2016: Oct 6. PMID: 27714434.
Pal SK, Agarwal N, Dizman N, Sonpavde G. Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. The Lancet Oncology. 2016: Oct 3. pii: S1470-2045(16)30493-4. doi: 10.1016/S1470-2045(16)30493-4. PMID: 27720137.
Bellmunt J, De Giorgi U, Sternberg Cn, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L, RISC Investigators. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European Urology. 2016: Oct 8. pii: S0302-2838(16)30682-0. doi: 10.1016/j.eururo.2016.09.042. PMID: 27726966.
Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal N. Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience. 2016: Sep 29. PMID: 27729941.
Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S Batten J, Reddy G, Bhat G, Sharma S, Agarwal N. A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer Chemotherapy Pharmacology. 2016: Oct 15. PMID: 27744565.
Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T, Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knoxx JJ, Pantuck A, Saleem S, Alva A, Rina BI, Lee JL, Choueiri TK, Heng DY. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. European Urology. 2016: Oct 19. PMID: 27771126.
Clark JI, Wong MK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S. Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM. Clinical Genitourinary Cancer. 2016: Oct 29. pii: S1558-7673(16)30317-2. doi: 10.1016/j.clgc.2016.10.008. PMID: 27916626.
Ramos JD, Casey MF, Crabb SJ, Bamias A, Harshman LC, Wong YN, Bellmunt J, Giorgi U, Ladoire S, Powles T, Pal SK, Niegisch G, Recine F, Alva A, Agarwal N, Necchi A, Vaishampayan UN, Rosenberg JE, Galsky MD, Yu EY, RISC Investigators. Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. Cancer Medicine. 2016: Dec 20. doi: 10.1002/cam4.986. PMID: 28000388.
Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung, Higano CS. Reply to M.A.N. Sendur et al and J. Michels. Journal of Clinical Oncology. 2017: Jan. PMID: 28034066.
Bailey EB, Merriman J, Maughan B, Poole A, Tantravahi SK, Agarwal AM, Batten JA, Patel SB, Pal SK, Stenejem DD, Agarwal N. Effect of treatment dose reductions in the setting of hang-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors. Journal of Oncology Pharmacy Practice. 2017: January 1. doi: 10.1177/1078155217693426. PMID: 28436250.
Kuzman JA, Stenehjem DD, Merriman J, Agarwal AM, Patel SB, Hahn AW, Alex A, Albertson D, Gill DM, Agarwal N. Neutrophl-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma. BMC Urology. 2017: Jan 5. doi:10.1186/s12894-016-0192-0. PMID: 28056941.
Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal N. Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clinical Genitourinary Cancer. 2017: Jan 5. pii: S1558-7673(16)30354-8. doi: 10.1016/j.clgc.2016.12.008. PMID: 28131750.
Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ. Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis. Clinical Genitourinary Cancer. 2017: Jan 5. pii: S1558-7673(16)30351-2. doi: 10.1016/j.clgc.2016.12.005. PMID: 28139444.
De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DY, Choueiri TK. Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 2017: Jan 12. pii: S1558-7673(17)30005-8. doi: 10.1016/j.clgc.2017.01.005. PMID: 28254206.
Gupta S, Gill D, Poole A, Agarwal N. Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions. Cancers. 2017: Jan 27. pii: E15. doi: 10.3390/cancers9020015. PMID: 28134806.
Narayan V, Keefe SM, Haas N, Wang L, Puzanov I, Putt ME, Catino A, Fang J, Agarwal N, Hyman D, Smith AM, Finkelman BS, Narayan HK, Ewer S, ElAmm C, Lenihan DJ, Ky B. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research. 2017: Feb 14. pii: clincanres.2869.2016. doi: 10.1158/1078-0432.CCR-16-2869. PMID: 28196874.
Agarwal N, Hahn AW, Gil DM, Farnham JM, Poole AI, Cannon-Albright L. Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer. JAMA Oncology. 2017: Feb 16. doi: 10.1001/jamaoncol.2017.0147. PMID: 28208175.
Motzer RJ, Figlin RA, Martini JF, Hariharan S, Agarwal N, Li CX, Williams JA, Hutson TE. Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results from the RENAL EFFECT Trial. Clinical Genitourinary Cancer. 2017: Feb 27. pii: S1558-7673(17)30049-6. doi: 10.1016/j.clgc.2017.02.006. PMID: 28330808.
Pal SK, Maia MC, Dizman N, Agarwal N. Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma? European Urology. 2017: March 14. pii: S0302-2838(17)30171-9. doi: 10.1016/j.eururo.2017.03.006. PMID: 28314610.
Gupta S, Greenberg S, Grimmett J, Gaston D, Agarwal N, Lowrance W, Schiffman J, Kohlmann W. Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. Familial Cancer. 2017: March 18. doi: 10.1007/s10689-017-9980-2. PMID: 28315974.
Flaig TW, Plets M, Hussain MH, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thomspon IM Jr. Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncology. 2017: March 30. doi: 10.1001/jamaoncol.2017.0231. PMID: 28358937.
Maughan BL, Bailey E, Gill DM, Agarwal N. Incidence of Immune-Related Adverse Events with Program Death Receptor-1-and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers. Frontiers in Oncology. 2017: April 3. doi: 10.3389/fonc.2017.00056. PMID: 28421161.
Hahn AW, Gill DM, Maughan B, Agarwal A, Arival L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal N. Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget. 2017: April 4. doi: 10.18632/oncotarget.16833. PMID: 28431395.
Pal SK, Sonpavde G, Agarwal N, Vogelzang NJ, Srinivas S, Haas NB, Signoretti S, McGregor BA, Jones J, Lanman RB, Banks KC, Choueiri TK. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eurpoean Urology. 2017: April 13. pii: S0302-2838(17)30277-4. doi: 10.1016/j.eururo.2017.03.046. PMID: 28413127.
Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC. Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Medicine. 2017: April 16. doi: 10.1002/cam4.1048. PMID: 28414866.
Gill DM, Sonpavde G, Pal SK, Agarwal N. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer. Journal of Immunotherapy. 2017: May 9. doi: 10.2217/imt-2017-0033. PMID: 28472906.
Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI. Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clinical Genitourinary Cancer. 2017: May 10. pii: S1558-7673(17)30138-6. doi: 10.1016/j.clgc.2017.05.014. PMID: 28579151.
Pal SK, Ali SM, Yakirevich E, Geynisman DM, Karam JA, Elvin JA, Frampton GM, Huang X, Lin DI, Rosenzweig M, Lipson D, Stephens PJ, Ross JS, Milller VA, Agarwal N, Shuch B, Choueiri TK, Chung JH. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. European Urology. 2017: May 30. pii: S0302-2838(17)30467-0. doi: 10.1016/j.eururo.2017.05.033. PMID: 28592388.
Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R. Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network (JNCCN). 2017: Jun 15. doi: 10.6004/jnccn.2017.0100. PMID: 28596261.
Gill DM, Agarwal N, Vaishampayan U. Evolving Treatment Paradigm in Metestatic Renal Cell Carcinoma. American Society of Clinical Oncology (ASCO) Educational Book. 2017: doi: 10.14694/EDBK_174469. PMID: 28561652.
Hahn AW, Gill DM, Pal SK, Agarwal N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017: June 9. doi: 10.2217/imt-2017-0024. PMID: 28653573.
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthoid DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist’s Perspective from a Multicentre Study. European Urology Focus. 2017. Mar 31. doi: 10.1016/j.euf.2017.03.011. PMID: 28753879.
Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K, Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothlium group. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European Urology Focus. 2017: Jun 3. doi: 10.1016/j.euf.2017.05.006. PMID: 28753897.
Shuch B, Hahn AW, Agarwal N. Current Treatment Landscape of Advanced Papillary Renal Cancer. Journal of Clinical Oncology. 2017: Jul 24. doi: 10.1200/JCO.2017.74.3328. PMID: 28737973.
Maia MC, Yang ES, Agarwal N, Pal SK. A step towards predicting checkpoint inhibitor response in kidney cancer. Lancet Oncology. 2017: Aug. doi: 10.1016/S1470-2045(17)30533-8. PMID: 28759367.
Hahn AW, Hale P, Rathi N, Agarwal N. Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. Current Opinion in Urology. 2017: Aug 14. doi: 10.1097/MOU.0000000000000443. PMID: 28816716.
Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, Agarwal N, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY, RISC Investigators. Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. Clinical Genitourinary Cancer. 2017: Aug 24. pii: S1558-7673(17)30242-2. doi: 10.1016/j.clgc.2017.08.001. PMID: 28923700.
Poole A, Gill D, Hahn AW, Johnson E, Carroll E, Boucher K, Nussenzveig R, Maughan B, Agarwal N. Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer. 2017: Sep 6. pii: S1558-7673(17)30272-0. doi: 10.1016/j.clgc.2017.08.017. PMID: 28958675.
Hahn AW, Gill DM, Agarwal N, Maughan BL. PD-1 checkpoint inhibition: Toxicities and management. Urologic Oncology. 2017. Sep 7. pii: S1078-1439(17)30412-X. doi: 10.1016/j.urolonc.2017.08.005. PMID: 28889921.
Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis SZ. Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System.Clinical Genitourinary Cancer. 2017: Clin Genitourin Cancer. 2017 Sep 7. pii: S1558-7673(17)30276-8. doi: 10.1016/j.clgc.2017.09.001. PMID: 28974397.
Smith-Cohn MA, Gill D, Voories BN, Agarwal N, Garrido-Laguna I. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy. 2017. Sep 9. doi: 10.2217/imt-2017-0042. PMID: 28877632.
Bergerot P, Agarwal N, Pal SK, Jones JO. Sarcomatoid Renal Cell Carcinoma: The Apple Doesn’t Fall Far From the Tree. Clinical Cancer Research. 2017. Sep 14. doi: 10.1158/1078-0432.CCR-17-2039. PMID: 28912138.
Hahn AW, Nussenzveig RH, Pal SK, Agarwal N. Blood-and tissue-based tumor genomics: a battle royale or match made in heaven? Annals of Oncology. 2017: Oct 1;28(10):2333-2335. doi: 10.1093/annonc/mdx418. PMID: 28945831.
Hahn AW, Pal SK, Agarwal N. HSD3B1-A Predictive Biomarker in Advanced Prostate Cancer. JAMA Oncology. 2017: Oct 12. doi: 10.1001/jamaoncol.2017.3158. PMID: 29049481.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of National Comprehensive Cancer Network (JNCCN). 2017: Oct 15. (10):1240-1267. doi: 10.6004/jnccn.2017.0156. PMID: 28982750.
Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Pal SK, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Neigisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishapayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Belmunt J, Galsky MD, RISC Investigators. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC). Annals of Oncology. 2017: Oct 25. doi: 10.1093/annonc/mdx692. PMID: 29077785.
Vogelzang, NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Advances in Therapy. 2017: Nov. doi: 10.1007/s12325-017-0628-2. PMID: 29076108.
Gill DM, Agarwal N. Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers. Urologic Oncology. 2017: Dec. pii: S1078-1439(17)30501-X. doi: 10.1016/j.urolonc.2017.09.023. PMID: 29054496.
Corn PG, Agarwal N, Araujo JC, Sonpavde G. Taxane-based Combination Therapies for Metastatic Prostate Cancer. European Urology Focus. 2017: Dec 20. pii: S2405-4569(17)30265-1. doi: 10.1016/j.euf.2017.11.009. PMID: 29275145.
Cheng HH, Plets M, Li H, Higano CS, Tangen CM, Agarwal N, Vogelzang NJ, Hussain M, Thompson IM Jr, Tewari M, Yu EY. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. The Prostate. 2018: Feb. doi: 10.1002/pros.23452. PMID: 29105802.
Catino AB, Hubbard RA, Chirinos JA, Townsend R, Keefe S, Haas NB, Puzanov I, Fang JC, Agarwal N, Hyman D, Smith AM, Gordon M, Plappert T, Englefield V, Narayan V, Ewer S, ElAmm C, Lenihan D, Ky B. Longitudinal Assessment of Vascular Function with Sunitinib in Patients With Metastatic Renal Cell Carcinoma. Circulation: Heart Failure. 2018: Mar. doi: 10.1161/CIRCHEARTFAILURE.117.004408. PMID: 29664405.
Hahn AW, Gill DM, Nussenzveig RH, Poole A, Farnham J, Cannon-Albright L, Agarwal N. G ermline Variant in HSD3B1 (1245 A > C) and Response to Abiraterone Acetate Plus Prednisone in Men With New-Onset Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 2018: Mar 27. pii: S1558-7673(18)30215-5. doi: 10.1016/j.clgc.2018.03.006. PMID: 29674118.
Stukalin I, Wells CJ, Fraccon A, Pasini F, Porta C, Lalani AA, Srinivas S, Bowman AI, Brugarolas J, Lee JL, Donskov F, Beuselinck B, Bamias A, Rini BI, Sim HW, Agarwal N, Rha SY, Kanesvaran R, Choueiri TK, Heng DYC. Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Kidney Cancer (IOS Press). 2018: Mar 30. DOI: 10.3233/KCA-170020.
Maia MC, Grivas P, Agarwal N, Pal SK. Circulating Tumor DNA in Bladder Cancer: Novel Applications and Future Directions. European Urology. 2018: Apr. doi: 10.1016/j.eururo.2017.10.011. PMID: 29097099.
Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthld DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD, Retrospective International Study of Invasive/Advanced Cancer of the Urothlium Group. Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clinical Genitourinary Cancer. 2018: Apr. doi: 10.1016/j.clgc.2017.10.012. PMID: 29158079.
Zhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, Llor X, Hofstatter E, Shuch B. Genetic testing for hereditary prostate cancer: Current status and limitations. 2018: Apr 18. doi: 10.1002/cncr.31316. PMID: 29669169.
Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Holmes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas P. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer. 2018: May 15. doi: 10.1002/cncr.31314. PMID: 29517810.
Hahn AW, Froerer C, VanAlstine S, Rathi N, Bailey EB, Stenehjem DD, Agarwal N. Targeting Bacteroides in Stool Microbiome and Response to Treatment with First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma. Clinical Genitourinary Cancer. 2018: May 29. pii: S1558-7673(18)30287-8. doi: 10.1016/j.clgc.2018.05.001. PMID: 29858123.
Hale P, Hahn AW, Rathi N, Pal SK, Haaland B, Agarwal N. Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. Journal of Geriatric Concology. 2018: May 31. pii: S1879-4068(18)30086-9. doi: 10.1016/j.jgo.2018.05.010. PMID: 29861146.
Dorff TB, Agarwal N. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. Asian Journal of Andrology. 2018: May-Jun. doi: 10.4103/aja.aja_12_18. PMID: 29553053.
Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data. Journal of Managed Care & Specialty Pharmacy. 2018: Jun. doi: 10.18553/jmcp.2018.24.6.525. PMID: 29799328.
Agarwal N, Lanman RB, Pal SK. Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. JAMA Oncology. 2018. July 19. doi: 10.1001/jamaoncol.2018.2317. PMID: 30027290.
Hahn AW, Pal SK, Agarwal N. Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. The Oncologist. 2018. Aug 23. doi: 10.1634/theoncologist.2018-0443. PMID: 30139834.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. Journal of National Comprehensive Cancer Network (JNCCN). 2018. Sep. doi: 10.6004/jnccn.2018.0072. PMID: 30181416.
Tripathi A, Agarwal N. Editorial Comment. The Journal of Urology. 2018. Sep 3. PMID: 30189185.
Rathi N, Anderson N, Greenberg S, Vagher J, Agarwal N, Hahn AW. DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC). World Journal of Oncology. 2018. Aug. doi: 10.14740/wjon1144w. PMID: 30220950.
Hahn AW, Higano CS, Taplin ME, Ryan CJ, Agarwal N. Metastatic Castration-Sensitive Prosate Cancer: Optimizing Patient Selection and Treatment. American Society of Clinical Oncology (ASCO) Educational Book. 2018. May 23. doi: 10.1200/EDBK_200967. PMID: 30231388.
Hamieh L, Choueiri TK, Ogorek B, Khabibullin D, Rosebrock D, Livitz D, Fay A, Pignon JC, McDermott DF, Agarwal N, Gao W, Signoretti S, Kwiatkowski DJ. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLOS Genetics. 2018. Sept 26. doi: 10.1371/journal.pgen.1007679. PMID: 30256787.
Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, Briganti A, Galsky MD. Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer. 2018. Sep 13. doi: 10.1016/j.clgc.2018.09.008. PMID: 30292628.
Twardowski PW, Tangen CM, Wu X, Plets MR, Plimack ER, Agarwal N, Vogelzang NJ, Wang J, Tao S, Thompson IM, Lara P. Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. Kidney Cancer. 2017. Nov 27; 1(2):123-132. PMID: 30334014.
Kroeger N, Li H, De Velasco G, Donskov F, Sim HW, Stuhler V, Wells JC, Stukalin I, Heide J, Bedke J, Agarwal N, Parekh H, Rini BI, Knox JJ, Pantuck A, Choueiri TK, Chin Heng DY. Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies. Clinical Genitourinary Cancer. 2018. Sep 12. [Epub ahead of print]. PMID: 30341028.
Agarwal N, Nussenzveig R, Pal SK. Biomarkers in renal-cell carcinoma: building on clinical paradigms. Lancet Oncology. 2018. Nov 8. [Epub ahead of print]. PMID: 30416074.
Del Bene G, Calabro F, Giannarelli D, Pilmack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN. Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. Fontiers in Oncology. 2018. Nov 19 ;8:463. eCollection 2018. PMID: 30510914.
Sirohi D, Smith SC, Agarwal N, Maughan BL. Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. Research and Reports in Urology. 2018. Nov 15; 10:205-217. eCollection 2018. PMID: 30510921.
Maughan BL, Pal SK, Gill D, Boucher K, Martin C, Salgia M, Nussenzveig R, Liu T, Hawks JL, Batten J, Nachaegari G, Stephenson R, Lowrance W, Jones J, Dechet C, Agarwal N. Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. The Oncologist. 2018. PMID: 30575560.
Hahn AW, Gill DM, Poole A, Nussenzveig RH, Wilson S, Farnham JM, Stephenson RA, Cannon-Albright LA, Maughan BL, Agarwal N. Germline Variant in SLCO2B1 and Reponse to Abriraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). Molecular Cancer Therapeutics. 2019. PMID: 30587554.
Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB. Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. Cancer. 2019. PMID: 30620391.
Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houlsworth J, Pal SK, Agarwal N. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. Plos One. 2019. PMID: 30682039.
Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Nachaegari G, Harwood D, Agarwal N. Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radition therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. Cancer Treatment and Research Communications. 2019. PMID: 30682445.
Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE. Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology. 2019. PMID: 30702028.
Esther J, Maughan BL, Anderson N, Agarwal N, Hahn AW. Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. Current Treatment Options in Oncology. 2019. PMID: 30741354.
Hahn AW, Stenehjem D, Nussenzveig R, Carroll E, Bailey E, Batten J, Maughan BL, Agarwal N. Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. Cancer Treatment and Research Communications. 2019. PMID: 30743187.
Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. Urologic Oncology. 2019. PMID: 30770300.
Esther J, Hale P, Hahn AW, Agarwal N, Maughan BL. Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. Drugs & Aging. 2019. PMID: 30784023.
Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 2019. PMID: 30817251.
Martinez Chanza N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. The Lancet Oncology. 2019. PMID: 30827746.
Hahn AW, Sirohi D, Agarwal N. The Role of PD-L1 Testing in Advanced Genitourinary Malignancies. European Urology Focus. 2019. PMID: 30872123.
Fishman M, Dutcher JP, Clark JI, Alva A, Miletello GP, Curti B, Agarwal N, Hauke R, Mahoney KM, Moon H, Treisman J, Tykodi SS, Daniels G, Morse MA, Wong MKK, Kaufman H, Gregory N, McDermott DF. Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM registry. Journal for Immunotherapy of Cancer. 2019. PMID: 30917871.
Swami U, Grivas P, Agarwal N. The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urotherlial Carcinoma. Oncologist. 2019. PMID: 30926675.
Bamias A, Tzannis K, Bamia C, Harshman LC, Crabb S, Plimack ER, Pal S, De Giorgi U, Ladoire S, Theodore C, Agarwal N, Yu EY, Niegisch G, Sternberg CN, Srinivas S, Vaishampayan U, Necchi A, Liontos M, Rosenberg JE, Powles T, Bellmunt J, Galsky MD. The impact of Cisplatin-or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist. 2019. PMID: 30936379.
Swami U, Nussenzveig RH, Haaland B, Agarwal N. Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. Annal of translational medicine. 2019. PMID: 31032299.
Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juarez Soto A, Merseburger AS, Ozguroglu M, Uemura H, Ye D, Deprince K, Naini V, Li J, Cheng S, Yu MK, Zhang K, Larsen JS, McCarthy S, Chowdhury S, TITAN Investigators. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. The New England Journal of Medicine. 2019. PMID: 31150574.
Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Lechuga MJ, Valota O, Shepard DR. A Phase 1b Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors (Epub ahead of print). Oncologist. 2019. PMID: 31171735.
Bandini M, Briganti A, Plimack ER, Niegisch G, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Theodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. Uropean Urology Oncology. 2019. PMID: 31200838.
Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. JCO Precision Oncology. 2019. PMID: 31218271.
Swami U, Pal SK, Agarwal N. Ideal Glucocorticoid Regimen With Abiraterone Acetate: Options and Challenges. JAMA Oncology. 2019. PMID: 31246246.
Pal SK, Swami U, Agarwal, N. Characterizing the Wnt Pathway in Advanced Prostate Cancer: When, Why, and How. European Urology. 2019. PMID: 31300236.
Pederzoli F, Bandini M, Briganti A, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Theodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A, RISC Investigators. Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. European Urology. 2019. PMID: 31303258.
Moschini M, Xylinas E, Zamboni S, Mattei A, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A, RISC Investigators. Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. European Urology Oncology. 2019. PMID: 31307962.
Hahn AW, Esther J, Haaland B, Swami U, Dizman N, Rathi N, Maughan BL, Pal SK, Agarwal N. Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. Journal of Geriatric Oncology. 2019. PMID: 31402176.
Martinez Chanza N, Werner L, Plimack E, Yu EY, Alva AS, Crabb SJ, Powles T, Rosenberg JE, Baniel J, Vaishampayan UN, Berthold DR, Ladoire S, Hussain SA, Milowsky MI, Agarwal N, Necchi A, Pal SK, Sternberg CN, Bellmunt J, Galsky MD, Harshman LC, RISC Investigators. Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. European Urology Oncology. 2019. PMID: 31411990.
Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde GP. Circulating Tumor DNA Alterations in Advanced Urothlial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European Urology Oncology. 2019. PMID: 31412004.
Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N. A Phase 1 Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Regractory Metestatic Renal Cell Carcinoma. The Oncologist. 2019. PMID: 31492769.
Nandagopal L, Sonpavde GP, Agarwal N. Investigational MET inhibitors to treat Renal cell carcinoma. Expert Opinion on Investigational Drugs. 2019. PMID: 31554440.
Pal S, Hu-Lieskovan S, Agarwal N. Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours? Lancet Oncology. 2019. PMID: 31563518.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Ozguroglu M, Juarez Soto A, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN, TITAN investigators. Health-related quality of life after apalutamide treatment in patients with metastatic castration-senstitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Lancet Oncology. 2019. PMID: 31578173.
Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, Wang X, Pal SK, Wallis CJD. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology Oncology. 2019. PMID: 31588018.
Hahn AW, Pal SK, Agarwal N. Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. The Oncologist. 2019. PMID: 31615950
Tripathi A, Lin E, Agarwal N. Biomarkers in metastatic renal cell carcinoma in the era of immune checkpoint inhibitors. Annals of Translational Medicine. 2019. PMID: 31656782.
Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA, CGC, Hammond LJ, Zuccarino-Catania G. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. Journal of the National Comprehensive Cancer Network (JNCCN). 2019. PMID: 31693980.
Ledet EM, Lilly MB, Sonpavde G, Lin E, Nussenzveig RH, Barata PC, Yandell M, Nagy RJ, Kiedrowski L, Agarwal N, Sartor O. Comprehensive Analysis of AR Alternations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. The Oncologist. 2019. PMID: 31712304.
Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, et al. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. European Urology. 2019. PMID: 31753752.
Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, Van Der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guidline. Journal of Clinical Oncology. 2019. PMID: 31829902.
Swami U, Yap JT, Agarwal N. Radioisotope Imaging and Therapy for Bone Metastasis in Men With Castration-Resistant Prostate Cancer. JAMA Oncology. 2019. PMID: 31830203.
Johnson E, Nussenzveig R, Agarwal N, Swami U. Germline variants and response to systemic therapy in advanced prostate cancer. Pharmacogenomics. 2020. PMID: 31849283.
Agarwal N, Nussenzveig RH, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks JL, Santos VS, Nachaegari G, Wang X, Boucher KM, Haaland B, Maughan BL. Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. Clinical Cancer Research. 2020. PMID: 31937614.
Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Holmes CJ, Shreck E, Asssi H, Gartrell BA, Sankin A, Rodriguez –Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Velho PI, Hahn N, Liu S, Buznego LA, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P. Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrosepctive Study. The Journal of urology. 2020. PMID: 31971495.
Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, Diefenbach CSM, Rodriguez-Galindo C, George DJ, Gilligan TD, Harvey RD, Johnson ML, Kimple RJ, Knoll MA, LoCente N, Maki RG, Meisel JL, Meyerhardt JA, Pennell NA, Rocque GB, Sabel MS, Schilsky RL, Schneider BJ, Tap WD, Uzzo RG, Westin SN. Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology. 2020. PMID: 32013670.
Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Carneiro BA, Fan AC, Brufsky AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clinical Cancer Research. 2020. PMID: 32034076.
Wong RL, Duong MT, Tangen CM, Agarwal N, Cheng HH, Vogelzang NJ, Hussain, M, Thompson IM JR, Quinn DI, Yu EY. Survival Outcomes and Risk Group Validation From SWOG S0925: A Randomized Phase II Study of Cixutumumab in New Metastatic Hormone-Sensitive Prostate Cancer. Prostate Cancer and Prostatic Diseases. 2020. PMID: 32055002.
Barata P, Swami U, Agarwal N. The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. Expert Review of Anticancer Therapy. 2020. PMID: 32068456.
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network (JNCCN). 2020. PMID: 32135513.
Bandini M, Pederzoli F, Madison R, Briganti A, Ross JS, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Pal SK, Galsky MD, Luciano R, Gallina A, Salonia A, Montorsi F, Ali SM, Chung JH, Necchi A. Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-insitutional Study. Clinical Genitourinary Cancer. 2020. PMID: 32144050.
Tward JD, O’Neil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C. Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clinical Genitourinary Cancer. 2020. PMID: 32335059.
McComas K, Agarwal N, Bowen G, Maughan BL, Tward JD. Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. Clinical Genitourinary Cancer. 2020. PMID: 32335061.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. Olaparib for Metastatic Castration-Resistant Prostate Cancer. The New England Journal of Medicine. 2020. PMID: 32343890.
Antonarakis ES, Isaacsson Velho P, Fu W, Wang H, Agarwal N, Sacristan Santos V, Maughan BL, Pili R, Adra N, Sternberg CN, Vlachostergios PJ, Tagawa ST, Bryce AH, McNatty AL, Reichert ZR, Dreicer R, Sartor O, Lotan TL, Hussain M. CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precision Oncology. 2020. PMID: 32462107.
Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, Bakouny Z, Agarwal N, Zakharia Y, Costello BA, McKay RR, Narayan V, Alva A, McGregor BA, Gao X, McDermott DF, Choueiri TK. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncology. 2020. PMID: 32469396.
McGregor BA, Gordon M, Flippot R, Agarwal N, George S, Quinn DI, Rogalski M, Hawthorne T, Keler T, Choueiri TK. Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Invest New Drugs. 2020. PMID: 32472319.
Bhowmick NA, Oft J, Dorff T, Pal S,Agarwal N, Figlin RA, Posadas EM, Freedland SJ, Gong J. COVID-19 and androgen-targeted therapy for prostate cancer patients. Endocrine-Related Cancer. 2020. PMID: 32508311.
Swami U, McFarland TR, Nussenzveig R,Agarwal N. Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends Cancer. 2020. PMID: 32534790.
Rathi N, Maughan BL,Agarwal N, Swami U. Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. Cancer Management and Research. 2020. PMID: 32547210.
Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH,Agarwal N, Jonasch E, Koh MY. Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clinical Cancer Research. 2020. PMID: 32586940.
Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES,Agarwal N. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. European Urology. 2020. PMID: 32624276.
Grunewald CM, Henn A, Galsky MD, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U,Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Sternberg CN, Bellmunt J, Baniel J, Niegisch G. Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. Urologic Oncology. PMID: 32660788.
Hahn AW,Agarwal N. The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas. Cancer Treatment and Research Communications. 2020. PMID: 32679555.
Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J,Agarwal N, Sartor O, Barata PC. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treatment and Research Communications. 2020. PMID: 32702615.
Tripathi A, Balakrishna P,Agarwal N. PARP inhibitors in castration-resistant prostate cancer. Cancer Treatment and Research Communications. 2020. PMID: 32745972.
Khaki AR,Agarwal N, Pal SK, Grivas P. Immunotherapy-based combination strategies for advanced urothelial cancer: A long quest. Cancer. 2020. PMID: 32757318.
Swami U, Nussenzveig RH,Agarwal N. Quest for Ideal Composite Biomarkers for Response to Immunotherapies. Clinical Cancer Research. 2020. PMID: 32759359.
Barata P,Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, Ledet E, Lewis B, Layton J, Babiker H, Bryce A, Garje R, Stein C, Kiedrowski L, Saylor P, Sartor O. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. Journal for Immunotherapy of Cancer. 2020. PMID: 32788235.
Fizazi K, Drake CG, Beer TM, Kwon ED, Scher HI, Gerritsen WR, Bossi A, den Eertwegh AJMV, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Danielli R, Franke FA, Sundar S,Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, McHenry MB, Chen A, Logothetis C; CA184-043, Investigators. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. European Urology. 2020. PMID: 32811715.
Swami U,Agarwal N. Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer. Cancer Treatment and Research Communications. 2020. PMID: 32822968.
Necchi A, Madison R, Pal SK, Ross JS,Agarwal N, Sonpavde G, Joshi M, Yin M, Miller VA, Grivas P, Chung JH, Ali SM. Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. European Urology Focus. 2020. PMID: 32861617.
Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B,Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network (JNCCN). 2020. PMID: 32886895.
Tripathi A, McFarland T,Agarwal N. PARP Inhibitors in Prostate Cancer: A Promise Delivered. European Urology Onoclogy. 2020. PMID: 32893185.
Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S,Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH. Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. JCO Precision Oncology. 2020. PMID: 32903788.
Boyle JL, Hahn AW, Kapron AL, Kohlmann W, Greenberg SE, Parnell TJ, Teerlink CC, Maughan BL, Feng BJ, Cannon-Albright L,Agarwal N, Cooney KA. Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer. JCO Precision Oncology. 2020. PMID: 32923906.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. The New England Journal of Medicine. 2020. PMID: 32955174.
Meza L, Bergerot PG, Agarwal N, Pal SK. Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe. Annals of Oncology. 2020. PMID: 33121996.
Swami U, Haaland B, Kessel A, Nussenzveig R, Maughan BL, Esther J, Sirohi D, Pal SK, Grivas P, Agarwal N. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum-Refractory Advanced Urothelial Carcinoma. The Journal of Urology. 2020. PMID: 33080152.
Cannon-Albright LA, Stevens J, Teerlink CC, Agarwal N. The HOXB13 p.Gly84Glu variant observed in an extended five generation high-risk prostate cancer pedigree supports risk association for multiple cancer sites. Cancer Epidemiology. 2020. PMID: 33099213.
Hwang JK, Agarwal N, Brugarolas J, Zhang T. Checking the Hippo in sarcomatoid renal cell carcinoma with immunotherapy. Clinical Cancer Research. 2020. PMID: 33106290.
Tripathi A, Lin E, Xie W, Flaifel A, Steinharter JA, Stern Gatof EN, Bouchard G, Fleischer JH, Martinez-Chanza N, Gray C, Mantia C, Thompson L, Wei XX, Giannakis M, McGregor BA, Choueiri TK,Agarwal N, McDermott DF, Signoretti S, Harshman LC. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. Journal for Immunotherapy of Cancer. 2020. PMID: 33177176.
Sena LA, Fountain J, Isaacsson Velho P, Lim SJ, Wang H, Nizialek E, Rathi N, Nussenzveig R, Maughan BL, Velez MG, Ashkar R, Larson AC, Pritchard CC, Adra N, Bryce AH, Agarwal N, Pardoll DM, Eshleman JR, Lotan TL, Antonarakis ES. Tumor frameshift mutation proportion predicts response to immunotherapy in mismatch repair-deficient prostate cancer. The Oncologist. 2020. PMID: 33215787.
Rathi N, McFarland TR, Nussenzveig R, Agarwal N, Swami U. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. Drugs. 2020. PMID: 33369720.
Swami U, Antonarakis ES,Agarwal N. Reply to Salma Kaochar, Nicholas Mitsiades’ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652-6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?: SPOP as a Potential Treatment Selection Marker in Prostate Cancer. European Urology. 2021. PMID: 33419681.
Khaki AR, Li A, Diamantopoulos LN, Miller NJ, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin V, Park J, Alva A, Bilen MA, Stewart T, Santos V, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. European Urology Oncology. 2021. PMID: 33423945.
Hahn AW, Bilen MA, Agarwal N. Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement. JAMA Network Open. 2021. PMID: 33496790.
Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM Jr, Agarwal N. Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). Clinical Cancer Research. 2021. PMID: 33500355.
Coletta AM, Rose NB, Johnson AF, Moxon DS, Trapp SK, Walker D, White S, Ulrich CM, Agarwal N, Oza S, Zingg RW, Hansen PA. The impact of a hospital-based exercise oncology program on cancer treatment-related side effects among rural cancer survivors. Supportive Care in Cancer. 2021. PMID: 33502590.
Coletta AM, Sayegh N, Agarwal N. Body composition and metastatic prostate cancer survivorship. Cancer Treatment and Research Communications. 2021. PMID: 33517236.
Swami U, Grivas P, Pal SK, Agarwal N. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. Cancer Treatment and Research Communications. 2021. PMID: 33549986.
Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU International. 2021. PMID: 33556233.
Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology. 2021. PMID: 33617303.
Desai A, Gainor JF, Hegde A, Schram AM, Curigiliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology. 2021. PMID: 33723371.
Palmbos PL, Daignault-Newton S, Tomlins SA, Agarwal N, Twardowski P, Morgans AK, Kelly WK, Arora VK, Antonarakis ES, Siddiqui J, Jacobson J, Davenport MS, Robinson DR, Chinnaiyan AM, Knudsen KE, Hussain M. A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone Sensitive Prostate Cancer (mHSPC). Clinical Cancer Research. 2021. PMID: 33727260.
Parikh M, Liu C, Wu CY, Evans CP, Dall’Era M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Scientific Reports. 2021. PMID: 33737681.
Mundle R, Afenya E, Agarwal N. The effectiveness of psychological intervention for depression, anxiety, and distress in prostate cancer: a systematic review of literature. Prostate Cancer Prostatic Dis. 2021. PMID: 33750905.
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer Clinical Trials Working Group. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 2021. PMID: 33758378.
Harrison MR, Costello BA, Bhavsar NA, Vaishampayan U, Pal SK, Zakharia Y, Jim HSL, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Inman BA, Mardekian J, Borham A, George DJ. Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). 2021. PMID: 33765337.
Sanchez A, Agarwal N. Quantifying the Costs of Care Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated in the Veterans Health Administration. JAMA Netw Open. 2021. PMID: 33787916.
Choueiri TK, Zakharia Y, Pal S, Kocsis J, Pachynski R, Poprach A, Nixon AB, Liu Y, Starr M, Lyu J, Owzar K, deShazo M, Lara P, Geczi L, Ho TH, Walsh M, Adams B, Robertson L, Darif M, Theuer C, Agarwal N. Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). Oncologist. 2021. PMID: 33829609.
Grivas P, Agarwal N, Pal S, Kalebasty AR, Sridhar SS, Smith J, Devgan G, Sternberg CN, Bellmunt J. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice. Cancer Treat Rev. 2021. PMID: 33839438.
Koh MY, Sayegh N, Agarwal N. Seeing the forest for the trees-single-cell atlases link CD8+ T cells and macrophages to disease progression and treatment response in kidney cancer. Cancer Cell. 2021. PMID: 33861995.
Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, Vaishampayan UN, Xie R, Bapat U, Ye W, Jain RK, Fishman MN. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. Eur Urol. 2021. PMID: 33867192.
Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez A, Merseburger AS, Özgüroğlu M, Uemura H, Ye D, Brookman-May S, Mundle SD, McCarthy SA, Larsen JS, Sun W, Bevans KB, Zhang K, Bandyopadhyay N, Agarwal N. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol. 2021. PMID: 33914595.
Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fléchon A, Jain RK, Agarwal N, Bupathi M, Barthelemy P, Beuzeboc P, Palmbos P, Kyriakopoulos CE, Pouessel D, Sternberg CN, Hong Q, Goswami T, Itri LM, Grivas P. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol. 2021. PMID: 33929895.
Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ. A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer. 2021. PMID: 33957901.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Soto ÁJ, Merseburger AS, Uemura H, Ye D, Given R, Basch E, Miladinovic B, Lopez-Gitlitz A, Chi KN. Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study. J Urol. 2021. PMID: 34039013.
Venkatachalam S, McFarland TR, Agarwal N, Swami U. Immune Checkpoint Inhibitors in Prostate Cancer. Cancers (Basel). 2021. PMID: 34063238.
Cannon-Albright LA, Teerlink CC, Stevens J, Huang FW, Sipeky C, Schleutker J, Hernandez R, Facelli J, Agarwal N, Trump DL. A Rare Variant in ERF (rs144812092) Predisposes to Prostate and Bladder Cancers in an Extended Pedigree. Cancers (Basel). 2021. PMID: 34063511.
Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY. Correction: Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res. 2021. PMID: 34074655.
Zengin ZB, Weipert C, Salgia NJ, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski L, Maughan BL, Rathi N, Goel D, Choueiri TK, Agarwal N, Pal SK. Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021. PMID: 34130999.
Giannarini G, Agarwal N, Apolo AB, Briganti A, Grivas P, Gupta S, Kamat AM, Montorsi F, Rouprêt M, Necchi A. Urologists, You’ll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2021. PMID: 34147473.
Sayegh N, Agarwal N, Swami U. Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. Eur Urol Oncol. 2021. PMID: 34148857.
Lin E, Hahn AW, Nussenzveig RH, Wesolowski S, Sayegh N, Maughan BL, McFarland T, Rathi N, Sirohi D, Sonpavde G, Swami U, Kohli M, Rich T, Sartor O, Yandell M, Agarwal N. Identification of Somatic Gene Signatures in Circulating Cell-Free DNA Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist. 2021. PMID: 34157173.
Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Soto ÁJ, Merseburger AS, Uemura H, Ye D, Given R, Basch E, Miladinovic B, Lopez-Gitlitz A, Chi KN. Reply by Authors. J Urol. 2021. PMID: 34296946.
Tripathi N, Agarwal N, Tripathi A. Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer. Oncologist. 2021. PMID: 34333836.
Costello BA, Bhavsar NA, Zakharia Y, Pal SK, Vaishampayan U, Jim H, Fishman MN, Molina AM, Kyriakopoulos CE, Tsao CK, Appleman LJ, Gartrell BA, Hussain A, Stadler WM, Agarwal N, Pachynski RK, Hutson TE, Hammers HJ, Ryan CW, Mardekian J, Borham A, George DJ, Harrison MR. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. Clin Genitourin Cancer. 2021. PMID: 34364796.
McFarland TR, Kessel A, Swami U, Agarwal N. Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations. Am J Transl Res. 2021. PMID: 34377227.
Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N. Radium-223 plus Enzalutamide versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist. 2021. PMID: 34423501.
Swami U, Agarwal N. Editorial Comment. J Urol. 2021. PMID: 34455827.
Sayegh N, Swami U, Agarwal N. Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncol Pract. 2021. PMID: 34473525.
Evans R, Hawkins N, Dequen-O’Byrne P, McCrea C, Muston D, Gresty C, Ghate SR, Fan L, Hettle R, Abrams KR, de Bono J, Hussain M, Agarwal N. Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). Target Oncol. 2021. PMID: 34478046.
Pal SK, McGregor B, Suárez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol. 2021. PMID: 34491815.
Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer. BJU Int. 2021. PMID: 34597472.
Hahn AW, George DJ, Agarwal N. An Evolving Role for AXL in Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2021. PMID: 34598944.
Swami U, Agarwal N. Drug development in metastatic prostate cancer: lessons from ACIS. Lancet Oncol. 2021. PMID: 34600603.
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer Prostatic Dis. 2021. PMID: 34621011.
Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN, Miller K, Jiao X, Guo H, Sandström P, Bruno A, Verholen F, Saad F, Shore N. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncol. 2022. PMID: 34636627.
Swami U, Sinnott JA, Haaland B, Sayegh N, McFarland TR, Tripathi N, Maughan BL, Rathi N, Sirohi D, Nussenzveig R, Kohli M, Pal SK, Agarwal N. Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. Cancers (Basel). 2021. PMID: 34638435.
Guha A, Gong Y, DeRemer D, Owusu-Guha J, Dent SF, Cheng RK, Weintraub NL, Agarwal N, Fradley MG. Cardiometabolic consequences of targeted anticancer therapies. J Cardiovasc Pharmacol. 2021. PMID: 34654781.
Hirsch L, Martinez Chanza N, Farah S, Xie W, Flippot R, Braun DA, Rathi N, Thouvenin J, Collier KA, Seront E, de Velasco G, Dzimitrowicz H, Beuselinck B, Xu W, Bowman IA, Lam ET, Abuqayas B, Bilen MA, Varkaris A, Zakharia Y, Harrison MR, Mortazavi A, Barthélémy P, Agarwal N, McKay RR, Brastianos PK, Krajewski KM, Albigès L, Harshman LC, Choueiri TK. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. JAMA Oncol. 2021.PMID: 34673916.
McFarland TR, Tandar CE, Agarwal N, Swami U. Emergence of polyclonal BRCA2 reversions following PARP inhibitor treatment: An illustrative case report. Cancer Treat Res Commun. 2021. PMID: 34700141.
Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES. Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2021. PMID: 34778690.
Swami U, Sayegh N, Agarwal N. Development of Novel Regimens Combining Immune Checkpoint Inhibitors and Radiation Therapy in Prostate Cancer. Eur Urol. 2021. PMID: 34895788.
Schmidt B, Agarwal N. Black Men Receiving Radiotherapy for Localized Prostate Cancer Have Improved Outcomes-Clinical Trial Access or Racial Advantage? JAMA Netw Open. 2021. PMID: 34964857.
Penson DF, Armstrong AJ, Concepcion RS, Agarwal N, Olsson CA, Karsh LI, Dunshee CJ, Duggan W, Shen Q, Sugg J, Haas GP, Higano CS. Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer Prostatic Dis. 2021. PMID: 34848822.
Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022. PMID: 34991070.
Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022. PMID: 35034502.
Carril-Ajuria L, Martin-Soberón MC, de Velasco G, Agarwal N, Castellano D. Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review. J Cancer Res Clin Oncol. 2022. PMID: 35064817.
Talukder R, Makrakis D, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lorenzo GD, Joshi M, Velho PI, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki AR. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. Clin Genitourin Cancer. 2022. PMID: 35078711.
Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Czibere A, Fizazi K. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Future Oncol. 2022. PMID: 35080190.
Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathi N, Sharma P, Agarwal N, Knudsen B. Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. Clin Genitourin Cancer. 2022. PMID: 35125301.
George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandström P, Verholen F, Higano CS, Shore N. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer Prostatic Dis. 2022. PMID: 35190653.
Mathew Thomas V, Tripathi N, Agarwal N, Swami U. Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. Expert Rev Anticancer Ther. 2022. PMID: 35249433.
Freeman MN, Jang A, Zhu J, Sanati F, Nandagopal L, Ravindranathan D, Desai A, Phone A, Nussenzveig R, Jaeger E, Caputo SA, Koshkin VS, Swami U, Basu A, Bilen MA, Agarwal N, Sartor O, Burgess EF, Barata PC. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. Oncologist. 2022. PMID: 35274720.
Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, Sayegh N, Lin DI, Raskina K, Schrock AB, Severson E, Haberberger JF, Ross JS, Creeden J, Levy MA, Alexander BM, Oxnard GR, Agarwal N. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. JAMA Netw Open. 2022. PMID: 35357449.
T’jollyn H, Ackaert O, Chien C, Lopez-Gitlitz A, McCarthy S, Ruixo CP, Karsh L, Chi K, Chowdhury S, Ruixo JP, Agarwal N. Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. Cancer Chemother Pharmacol. 2022. PMID: 35366072.
Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM Jr, Quinn DI. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol. 2022. PMID: 35446628.
Weiner AB, Siebert AL, Fenton SE, Abida W, Agarwal N, Davis ID, Dorff TB, Gleave M, James ND, Poon DMC, Suzuki H, Sweeney CJ. First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. Eur Urol Oncol. 2022. PMID: 35641398.
Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022. PMID: 35690072.
Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Jang A, Barata P, Sonpavde G, Yu EY, Montgomery RB, Grivas P, Khaki AR. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022. PMID: 35778337.
Morgan G, Agarwal N, Choueiri TK, Dizon DS, Hamilton EP, Markham MJ, Lewis M, Prowell TM, Rugo HS, Subbiah V, West HL. The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. Cancer Discov. 2022. PMID: 35791692.
Guha A, Sayegh N, Agarwal N. Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies. JACC CardioOncol. 2022. PMID: 35818554.
Sayegh N, Tripathi N, Nussenzveig RH, Thomas VM, Tandar C, Goel D, Nordblad B, Sahu KK, Li H, L Maughan B, Agarwal N, Swami U. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. Eur Urol Focus. 2022. PMID: 35835693.
Sahu KK, Tripathi N, Agarwal N, Swami U. Relugolix in the management of prostate cancer. Expert Rev Anticancer Ther. 2022. PMID: 35866612.
Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi D. Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urol Oncol. 2022. PMID: 35918248.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022. PMID: 35948037.
Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Czibere A, Fizazi K. Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. Future Oncol. 2022. PMID: 35950899.
Zimmerman R, Bilen MA, Heath EI, Nandagopal L, Swami U, Kessel A, Jaeger E, Wesolowski S, Hernanadez EJ, Chipman J, Mack A, Ravindranathan D, Maughan BL, Nussenzveig R, Yandell M, Kohli M, Lilly MB, Sartor AO, Agarwal N, Barata PC. Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on Race. Oncologist. 2022. PMID: 36036607.
Chi KN, Barnicle A, Sibilla C, Lai Z, Corcoran C, Barrett JC, Adelman CA, Qiu P, Easter A, Dearden S, Oxnard GR, Agarwal N, Azad A, de Bono J, Mateo J, Olmos D, Thiery-Vuillemin A, Harrington EA. Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound. Clin Cancer Res. 2022. PMID: 36043882.
Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O Jr, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Sepúlveda Sánchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022. PMID: 36048457.
Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, Li G, Ross JS, Sayegh N, Tripathi N, Mathew Thomas V, Oxnard GR, Antonarakis ES, Agarwal N. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res. 2022. PMID: 36088616.
Green YS, Ferreira Dos Santos MC, Fuja DG, Reichert EC, Campos AR, Cowman SJ, Acuña Pilarte K, Kohan J, Tripp SR, Leibold EA, Sirohi D, Agarwal N, Liu X, Koh MY. ISCA2 inhibition decreases HIF and induces ferroptosis in clear cell renal carcinoma. Oncogene. 2022. PMID: 36097192.
Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, Agarwal N, Swami U. A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. Heliyon. 2022. PMID: 36120495.
Talukder R, Makrakis D, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, Carril-Ajuria L, Castellano D, de Kouchkovsky I, Jindal T, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Tripathi N, Agarwal N, Vather-Wu N, Zakharia Y, Morales-Barrera R, Devitt ME, Cortellini A, Fulgenzi CAM, Pinato DJ, Nelson A, Hoimes CJ, Gupta K, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Fröbe A, Rodriguez-Vida A, Drakaki A, Liu S, Lu E, Kumar V, Lorenzo GD, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Wright JL, Yu EY, Montgomery RB, Hsieh AC, Grivas P, Khaki AR. Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022. PMID: 36155169.
Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N. Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA. Front Oncol. 2022. PMID: 36185208.
Sayegh N, Tripathi N, Agarwal N, Swami U. Clinical Evidence and Selecting Patients for Treatment with Erdafitinib in Advanced Urothelial Carcinoma. Onco Targets Ther. 2022. PMID: 36186154.
Swami U, Sayegh N, Jo Y, Haaland B, McFarland TR, Nussenzveig RH, Goel D, Sirohi D, Hahn AW, Maughan BL, Goldkorn A, Agarwal N. External validation of association of baseline circulating tumor cell counts with survival outcomes in men with metastatic castration-sensitive prostate cancer. Mol Cancer Ther. 2022. PMID: 36198026.
Bakouny Z, El Zarif T, Dudani S, Connor Wells J, Gan CL, Donskov F, Shapiro J, Davis ID, Parnis F, Ravi P, Steinharter JA, Agarwal N, Alva A, Wood L, Kapoor A, Ruiz Morales JM, Kollmannsberger C, Beuselinck B, Xie W, Heng DYC, Choueiri TK. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2022. PMID: 36272943.
Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, Ürün Y, van Alphen R, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld E, Kramer G, Agarwal N, Chi KN, Dearden S, Gresty C, Kang J, Poehlein C, Harrington EA, Hussain M. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA. Clin Cancer Res. 2022. PMID: 36318705.
Azad AA, Kostos L, Agarwal N. KIT as a therapeutic target in neuroendocrine prostate cancer. Cancer Cell. 2022. PMID: 36332623.
Su CT, Nizialek E, Berchuck JE, Vlachostergios PJ, Ashkar R, Sokolova A, Barata PC, Aggarwal RR, McKay RR, Agarwal N, McClure HM, Nafissi N, Bryce AH, Sartor O, Sayegh N, Cheng HH, Adra N, Sternberg CN, Taplin ME, Cieslik M, Alva AS, Antonarakis ES. Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer. Prostate. 2022. PMID: 36382533.
Winter JM, Fresenius HL, Cunningham CN, Wei P, Keys HR, Berg J, Bott A, Yadav T, Ryan J, Sirohi D, Tripp SR, Barta P, Agarwal N, Letai A, Sabatini DM, Wohlever ML, Rutter J. Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunction. Elife. 2022. PMID: 36409067.
Makrakis D, Bakaloudi DR, Talukder R, Lin GI, Diamantopoulos LN, Jindal T, Vather-Wu N, Zakharia Y, Tripathi N, Agarwal N, Dawsey S, Gupta S, Lu E, Drakaki A, Liu S, Zakopoulou R, Bamias A, Fulgenzi CM, Cortellini A, Pinato D, Barata P, Grivas P, Khaki AR, Koshkin VS. Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022. PMID: 36481176.
Sahu KK, Agarwal N.J Urol. Editorial Comment. J Urol. 2023. PMID: 36484444.
Chawla NS, Sayegh N, Tripathi N, Govindarajan A, Zengin ZB, Phillip EJ, Dizman N, Meza L, Muddasani R, Chehrazi-Raffle A, Malhotra J, Hsu J, Agarwal N, Pal SK, Tripathi A. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors. Clin Genitourin Cancer. 2022. PMID: 36509613.
McFarland TR, Mathew Thomas V, Nussenzveig R, Gebrael G, Sayegh N, Tripathi N, Sahu KK, Goel D, Maughan BL, Sirohi D, Agarwal N, Swami U. Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting. Biomedicines. 2022. PMID: 36551924.
Takemura K, Navani V, Ernst MS, Wells JC, Meza L, Pal SK, Lee JL, Li H, Agarwal N, Alva AS, Hansen AR, Basappa NS, Szabados B, Powles T, Tran B, Hocking CM, Beuselinck B, Yuasa T, Choueiri TK, Heng DYC. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. J Urol. 2022. PMID: 36573926.
Swaby J, Aggarwal A, Batra A, Jain A, Seth L, Stabellini N, Bittencourt MS, Leong D, Klaassen Z, Barata P, Sayegh N, Agarwal N, Terris M, Guha A. Association of Androgen Deprivation Therapy with Metabolic Disease in Prostate Cancer Patients: An Updated Meta-Analysis. Clin Genitourin Cancer. 2022. PMID: 36621463.
Swami U, Hong A, El-Chaar NN, Ramaswamy K, Diessner BJ, Blauer-Peterson CJ, Sandin R, Nimke D, Agarwal N. The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer. J Urol. 2023. PMID: 36789668.
Sayegh N, Yirerong J, Agarwal N, Addison D, Fradley M, Cortes J, Weintraub NL, Sayed N, Raval G, Guha A. Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors. Curr Cardiol Rep. 2023. PMID: 36795308.
Stabellini N, Cullen J, Moore JX, Cao L, Agarwal N, Hamerschlak N, Waite K, Montero AJ, Barnholtz-Sloan JS, Guha A. Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer. JACC CardioOncol. 2022. PMID: 36909936.
Lim EA, Schweizer MT, Chi KN, Aggarwal R, Agarwa N, Gulley J, Attiyeh E, Greger J, Wu S, Jaiprasart P, Loffredo J, Bandyopadhyay N, Xie H, Hansen AR. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023. PMID: 36948922.
Li H, Sahu KK, Brundage J, Benson M, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan BL. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. Oncologist. 2023. PMID: 36952231.
Gebrael G, Thomas VM, Swami U, Agarwal N. The Management of Metastatic Castrate-Senstitive Prostate Cancer: From Guidelines to Real-World Practice. Oncologist. 2023. PMID: 37014098.
Cannon-Albright LA, Stevens J, Facelli JC, Teerlink CC, Allen-Brady K, Agarwal N. High-Risk Pedigree Study Identifies LRBA (rs62346982) as a Likely Predisposition Variant for Prostate Cancer. Cancers (Basel). 2023. PMID: 37046747.
Gebrael G, Sahu KK, Agarwal N, Maughan BL. Update on combined immunotherapy for the treatment of advanced renal cell carcinoma. Hum Vaccin Immunother. 2023. PMID: 37062953.
Lara PN Jr, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn DI, LeBlanc M, Vogelzang NJ, Thompson I, Agarwal N. Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. Eur Urol. 2023. PMID: 37085425.

Neeraj Agarwal

Publications (PubMed ID)

Follow me on Twitter

Neeraj Agarwal

Publications (PubMed ID)

Share this:

Like this:

Follow me on Twitter